Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

Name: EU clinical trials authorised under CTIS
Creator: Priya Life Science
License: https://www.ema.europa.eu/en/about-us/legal-notice

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12777 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Nov 2026, 03:17 UTC

2556

Shown in this register

most recently authorised

12,777

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547

Narrow the registerReset

Search within results

Phase

Lead sponsor

Clear sponsor filter

Member state

All 28 states

Trials in this register

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase I

A clinical trial of MK-4605 in healthy participants (MK-4605-002)

2026-527786-30-00Dementia

Merck Sharp & Dohme LLC

Nervous System Diseases

Belgium

04/11/2026

Phase I

A clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001)

2026-526983-19-00Prostate Cancer

Merck Sharp & Dohme LLC

Neoplasms

Netherlands

03/11/2026

Phase I

A clinical trial of MK-7228 in healthy participants (MK-7228-003)

2026-528069-38-00Atherosclerosis

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

23/10/2026

Phase II

A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK- 1045 in Participants with Hematologic Malignancies

2025-522242-49-00CLL/SLL

DrugsMK-1045·Tocilizumab

Merck Sharp & Dohme LLC

Neoplasms

Spain, Italy

15/10/2026

Phase II

LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors

2025-524515-37-00Neoplasm malignant

DrugBelzutifan

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Spain, Denmark, Italy, France

05/10/2026

Phase I

A clinical trial of MK-3586 in healthy participants (MK-3586-001)

2026-527250-39-00Rheumatoid arthritis

Merck Sharp & Dohme LLC

Immune System Diseases

Belgium

30/09/2026

Phase I

A clinical trial of MK-1824 in healthy participants (MK-1824-002)

2026-527518-22-00Heart failure with preserved ejection fraction

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

23/09/2026

Phase I

A clinical trial of MK-8210 in healthy participants (MK-8210-001)

2026-527022-13-00HIV-1 (Human Immunodeficiency Virus Type 1)

Merck Sharp & Dohme LLC

Virus Diseases

Belgium

19/08/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

2025-525102-38-00Elevated lipoprotein(a)

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Netherlands, Denmark, Germany, Spain

18/08/2026

Phase I

A clinical trial of MK-3868 in healthy participants (MK-3868-001)

2026-526674-17-00Malaria

Merck Sharp & Dohme LLC

Parasitic Diseases

Belgium

27/07/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase III

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

2025-522643-18-00Stage I NSCLC

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Neoplasms

Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain

16/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Netherlands, France, Germany, Spain, Poland, Greece

12/06/2026

Phase III

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

2025-522267-15-00Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Merck Sharp & Dohme LLC

Neoplasms

Greece, Netherlands, Sweden, France, Italy, Spain, Denmark

12/06/2026

Phase III

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

2025-522777-10-00Follicular Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Germany, Greece, Italy, Poland

09/06/2026

Phase I/II

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

2025-521032-11-00Small cell lung cancer extensive stage

Merck Sharp & Dohme LLC

Neoplasms

Germany, Poland, Greece, Italy, France, Spain

08/06/2026

Phase I/II

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

2025-523005-15-00Non-Hodgkin Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

Poland, Italy, France, Germany, Spain

28/05/2026

Phase I/II

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

2025-522339-32-00Neoplasm malignant

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia

26/05/2026

Phase I

A clinical trial of MK-1824 in healthy participants (MK-1824-001)

2026-525748-14-00Heart failure with preserved ejection fraction

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

12/05/2026

Phase II

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

2026-525213-31-00Esophageal squamous cell carcinoma

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Germany, France, Norway

12/05/2026

Phase I

A clinical trial of MK-4605 in healthy participants (MK-4605-001)

2026-525627-24-00Dementia

Merck Sharp & Dohme LLC

Nervous System Diseases

Belgium

06/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)

2024-516993-31-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece

04/05/2026

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

2025-520997-21-00Psoriatic arthritis

Merck Sharp & Dohme LLC

Musculoskeletal Diseases

Poland, Germany, Spain

30/04/2026

Phase III

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark

28/04/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)

2023-508047-40-00Ovarian cancer

Merck Sharp & Dohme LLC

Neoplasms

Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden

28/04/2026

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

2024-517337-41-00Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated N…

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Germany, Poland, Greece, France

20/04/2026

Phase III

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

2024-520014-22-00Locally advanced/metastatic urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France

20/04/2026

Phase I

A clinical trial of MK-6050 in healthy participants (MK-6050-002)

2026-525625-21-00Hidradenitis

Merck Sharp & Dohme LLC

Immune System Diseases

Belgium

13/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

2025-520902-37-00Non-small cell lung cancer stage IV

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Poland, France

23/03/2026

Phase I

A clinical trial of MK-7228 in adults (MK-7228-002)

2025-522147-18-00Atherosclerosis

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

17/03/2026

Phase I

A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)

2025-524852-74-00Hypercholesterolaemia

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Belgium

06/03/2026

Phase I/II

Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

2024-512248-47-00Non-small Cell Lung Cancer (NSCLC)

DrugsCalderasib·Patritumab deruxtecan·Sacituzumab tirumotecan·Cetuximab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Germany, Greece, Poland, Hungary, Spain

04/03/2026

Phase I

A clinical trial of MK-6916 in healthy participants (MK-6916-010)

2025-524570-41-00Acute and Chronic pain

Merck Sharp & Dohme LLC

Nervous System Diseases

Belgium

02/03/2026

Phase II

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …

Merck Sharp & Dohme LLC

Neoplasms

Italy, Poland, Spain, Finland, Netherlands, Greece

24/02/2026

Phase III

A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV 1

2025-522519-40-00HIV

Merck Sharp & Dohme LLC

Virus Diseases

France, Spain

16/02/2026

Phase I/II

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D

2025-522253-19-00Urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, France, Spain

03/02/2026

Phase I

A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)

2025-523412-36-00Systemic lupus erythematosus, Rheumatoid arthritis

Merck Sharp & Dohme LLC

Immune System Diseases

Italy, Belgium, Romania, Spain

02/02/2026

Phase III

An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia

2024-519068-42-00Heterozygous Familial Hypercholesterolemia in pediatric p…

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland

26/01/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

2025-521514-26-00Persistent, Recurrent, or Newly Diagnosed Metastatic Cervic…

Merck Sharp & Dohme LLC

Neoplasms

Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy

14/01/2026

Phase I/II

A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

2025-522495-84-00Cancer – Solid Tumors : 1L NSCLC and all other advanced or …

Merck Sharp & Dohme LLC

Neoplasms

Spain

23/12/2025

Phase I/II

Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…

DrugMK-3120

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France

22/12/2025

Phase III

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)

2025-521970-33-00Pulmonary Arterial Hypertension (PAH)

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands

01/12/2025

Phase III

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

2024-514500-14-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …

Merck Sharp & Dohme LLC

Neoplasms

Germany, Italy, France, Poland, Spain, Hungary, Romania, Greece, Austria, Netherlands, Belgium

27/11/2025

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

2025-521495-54-00Hyperlipidemia

Merck Sharp & Dohme LLC

Cardiovascular Diseases

Spain, Hungary

19/11/2025

Phase I

A clinical study of MK-6050 in healthy people (MK-6050-001)

2025-523861-58-00Hidradenitis suppurativa

Merck Sharp & Dohme LLC

Immune System Diseases

Belgium

12/11/2025

Phase II

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

2025-521737-91-00Neoplasm malignant with KRAS G12C mutation

Merck Sharp & Dohme LLC

Neoplasms

Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece

12/11/2025

Phase III

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

2024-517136-21-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland

10/11/2025

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

2025-521059-21-00Radiographic axial spondyloarthritis (as known as ankylosin…

Merck Sharp & Dohme LLC

Musculoskeletal Diseases

Netherlands, Germany, Poland

30/10/2025

Phase II

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis

2025-521745-25-00Rheumatoid Arthritis

Merck Sharp & Dohme LLC

Immune System Diseases

Poland, Spain, Germany

27/10/2025

Phase I

A clinical study of MK-4082 in healthy people (MK-4082-001)

2025-522100-25-00Weight management

Merck Sharp & Dohme LLC

Nutritional and Metabolic Diseases

Belgium

08/10/2025

Phase III

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis

2025-520610-58-00HIV-1 prevention

Merck Sharp & Dohme LLC

Virus Diseases

France

03/10/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,777 trial records at the last sync on 06 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 51 of those trials that match the filters currently applied.

How many clinical trials does CTIS hold?

CTIS held 12,777 trial records at the last sync. Of the 2,556 most recently authorised trials shown in this register, 789 are Phase III, and 51 match the filters currently applied. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase, 51 trials
Phase	Trials	Share
Phase III	17	33.3%
Phase I	16	31.4%
Phase II	11	21.6%
Phase I/II	7	13.7%

Most active sponsors

Lead sponsors with the most trials
Lead sponsor	Trials
Merck Sharp & Dohme LLC	51

Member states with the most trials

Member states by number of trials with a site there
Member state	Trials
Spain	32
Belgium	26
France	26
Italy	25
Germany	24
Poland	22
Greece	18
Netherlands	17
Denmark	11
Czechia	9

→

Browse trials by member state

Spain (1075) France (930) Germany (898) Italy (778) Poland (619) Netherlands (547) Belgium (455) Czechia (341) Denmark (319) Hungary (254) Greece (237) Austria (219) Romania (219) Bulgaria (218) Sweden (200)

→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Breast Cancer (11) Ulcerative colitis (11) Prostate Cancer (10)

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.